The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...